Search - tctmd.com

Displaying 1 - 10 of 10

Sort: Relevancy | Date

June 2024 Dispatch for the CV Team

News Opinion CV Team Dispatch

June 2024 Dispatch for the CV Team

June 01, 2024

Mechanism’s Mojo ‘Obvious’ CV Therapies More Likely to Be Seen as Effective

News Daily News

Mechanism’s Mojo: ‘Obvious’ CV Therapies More Likely to Be Seen as Effective

Michael O'Riordan

February 23, 2024

TCTMD’s Top 10 Most Popular Stories for December 2023

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for December 2023

December 28, 2023

TCTMD’s Top 10 Most Popular Stories for March 2021

News Daily News

TCTMD’s Top 10 Most Popular Stories for March 2021

April 02, 2021

Roughly 80% of ESC Guideline Writers Have Financial COIs

News Features

Roughly 80% of ESC Guideline Writers Have Financial COIs

Michael O'Riordan

April 01, 2021

News Daily News

FDA Approves Two Generic Versions of Apixaban

December 23, 2019

Andexanet Alfa, First Reversal Agent for Factor Xa Inhibitors, Finally Gains FDA Approval

News Daily News

Andexanet Alfa, First Reversal Agent for Factor Xa Inhibitors, Finally Gains FDA Approval

May 04, 2018

Year in Review: Physicians Pick the Biggest News of 2017, in Interventional Cardiology and Beyond

News Daily News

Year in Review: Physicians Pick the Biggest News of 2017, in Interventional Cardiology and Beyond

December 26, 2017

News Daily News

Betrixaban Approved for Prevention of VTE

Michael O'Riordan

June 23, 2017

News Daily News

FDA Declines to Approve Portola’s Reversal Agent for Factor Xa Inhibitors

Michael O'Riordan

August 18, 2016

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.